 BiondVax Pharmaceuticals Ltd. Nasdaq: BVXV, a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, announced that effective January 16, 2020, the Company will permit holders of all outstanding warrants of the Company Warrants issued to investors in connection with its initial public offering on Nasdaq the Warrant holders to exercise their warrants on a cashless exercise basis. Warrant holders will continue to be able to exercise their Warrants on a cash basis as well. No other terms of the Warrants are being amended. 